Claris Lifesciences dips after block deal
The stock dipped 13% to Rs 270, falling 19% from its intra-day high of Rs 334, on the Bombay Stock Exchange.
 "Claris Lifesciences dips after block deal")
Shares of Claris Lifesciences have dipped 13% to Rs 270, falling 19% from its intra-day high, following a huge block deal on the the Bombay Stock Exchange (BSE).
At 1318 hours, around 4.85 million equity shares representing nearly 9% of total equity of Claris Lifesciences changed hands on the counter at price of Rs 286 per share, the BSE data shows.
The stock opened 8% higher at Rs 334 after the pharmaceutical company announced settlement of litigation and license agreement for its generic DIPRIVAN in USA. CLICK HERE TO READ FULL REPORT.
Till 1327 hours, about 5.78 million shares changed hands against an average sub 500,000 shares that were traded daily in past two weeks on the BSE.
At 1318 hours, around 4.85 million equity shares representing nearly 9% of total equity of Claris Lifesciences changed hands on the counter at price of Rs 286 per share, the BSE data shows.
The stock opened 8% higher at Rs 334 after the pharmaceutical company announced settlement of litigation and license agreement for its generic DIPRIVAN in USA. CLICK HERE TO READ FULL REPORT.
Till 1327 hours, about 5.78 million shares changed hands against an average sub 500,000 shares that were traded daily in past two weeks on the BSE.